Sanders Morris Harris LLC Acquires New Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Sanders Morris Harris LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 18,600 shares of the company’s stock, valued at approximately $336,000. Other hedge funds have also bought and sold shares of the company. Tower […]

Related Keywords

Richard Scott Struthers ,Marc Wilson ,Robertw Baird ,Zurcher Kantonalbank Zurich Cantonalbank ,Cantor Fitzgerald ,News Ratings For Crinetics Pharmaceuticals Daily ,Bourgeon Capital Management ,Nasdaq ,Quarter For Crinetics Pharmaceuticals ,Crinetics Pharmaceuticals Inc ,Cubist Systematic Strategies ,Crinetics Pharmaceuticals Company Profile ,Crinetics Pharmaceuticals ,Tower Research Capital ,Crinetics Pharmaceuticals Stock ,Sanders Morris Harris ,Securities Exchange Commission ,Group One Trading ,Free Report ,Research Capital ,Capital Management ,Kantonalbank Zurich Cantonalbank ,Systematic Strategies ,Scott Struthers ,Exchange Commission ,Get Free Report ,Visit Holdingschannel ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,